<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">neurosurgery</journal-id><journal-title-group><journal-title xml:lang="ru">Нейрохирургия</journal-title><trans-title-group xml:lang="en"><trans-title>Russian journal of neurosurgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1683-3295</issn><issn pub-type="epub">2587-7569</issn><publisher><publisher-name>Издательский дом "МедИНК"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.63769/1683-3295-2025-27-3-143-151</article-id><article-id custom-type="elpub" pub-id-type="custom">neurosurgery-1723</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FOR PRACTITIONERS</subject></subj-group></article-categories><title-group><article-title>Техника подкожного введения лекарственных препаратов: работа над ошибками. Обзор литературы и собственный опыт на примере препарата Тафалгин</article-title><trans-title-group xml:lang="en"><trans-title>Technique of subcutaneous drug administration: correction of mistakes. Literature review and first-hand experience in administering Tafalgin</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ильин</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ilyin</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ильин Сергей Александрович.</p><p>143442 Московская обл., Красногорск, п. Отрадное, 2, стр. 1</p></bio><bio xml:lang="en"><p>Sergey A. Ilyin.</p><p>Bld. 1, 2 Otradnoye, Krasnogorsk, Moscow Region 143442</p></bio><email xlink:type="simple">doc.69@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2604-3485</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демьяновская</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Demyanovskaya</surname><given-names>E. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>125310 Москва, Волоколамское шоссе, 63, стр. 2; 121359 Москва, ул. Маршала Тимошенко, 19, стр. 1А</p></bio><bio xml:lang="en"><p>Bld. 2, 63 Volokolamskoye Shosse, Moscow 125310; Bld. 1A, 19 Marshala Timoshenko St., Moscow 121359</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5629-9860</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Генов</surname><given-names>П. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Genov</surname><given-names>P. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>123182 Москва, ул. Пехотная, 3; 197183 Санкт-Петербург, ул. Савушкина, 78, кв. 7</p></bio><bio xml:lang="en"><p>3 Pekhotnaya St., Moscow 123182; Apt. 7, 78 Savushkina St., Saint Petersburg 197183</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Клиническая больница АО «Группа компаний «Медси»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Clinical Hospital of “Medsi” Group of Companies</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «Инфекционная клиническая больница № 1 Департамента здравоохранения г. Москвы»; ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Infectious Clinical Hospital No. 1, Moscow Healthcare Department; Central State Medical Academy, Presidential Administration of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ «Московский клинический научно-исследовательский центр Больница 52 Департамента здравоохранения г. Москвы»; НО «Ассоциации интервенционного лечения боли»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Clinical Research Center Hospital 52, Moscow Healthcare Department; Associations of Interventional Pain Management</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>10</month><year>2025</year></pub-date><volume>27</volume><issue>3</issue><fpage>143</fpage><lpage>151</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ильин С.А., Демьяновская Е.Г., Генов П.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Ильин С.А., Демьяновская Е.Г., Генов П.Г.</copyright-holder><copyright-holder xml:lang="en">Ilyin S.A., Demyanovskaya E.G., Genov P.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.therjn.com/jour/article/view/1723">https://www.therjn.com/jour/article/view/1723</self-uri><abstract><p>В статье рассмотрены особенности и преимущества подкожного введения лекарственных средств на примере пептидного анальгетика – препарата Тафалгин, применяемого в нейрохирургической практике. Акцентировано внимание на необходимости правильной техники выполнения подкожных инъекций, указаны ошибки при подкожном введении лекарственных препаратов и их возможные последствия. Представлен пошаговый алгоритм действий, который позволит избежать нарушения правильной техники выполнения подкожных инъекций, включая выбор оптимального участка для подкожных инъекций, шприца и иглы, подготовку кожи в месте предполагаемой инъекции и непосредственно сам процесс ее проведения. Описаны особенности подкожного введения препарата Тафалгин, приведен пример нарушения техники выполнения подкожной инъекции препарата Тафалгин, следствием которого может стать непреднамеренное внутримышечное введение препарата. Представлены сформулированные авторами положения по оптимальному способу введения препарата Тафалгин, которые позволят минимизировать технические ошибки при проведении подкожной инъекции в клинической работе врачей.</p></abstract><trans-abstract xml:lang="en"><p>The article discusses the features and advantages of subcutaneous administration of drugs using the peptide analgesic Tafalgin as an example, which is used in neurosurgical practice. The focus is on the need for proper technique for performing subcutaneous injections, common mistakes in subcutaneous administration of drugs and their possible consequences. A step-by-step algorithm of actions is provided, which is designed to avoid violating the correct technique for performing subcutaneous injections. In particular, the article discusses the choice of the optimal site for subcutaneous injections, the choice of a syringe and needle for this procedure, the preparation of the skin at the site of the intended injection, and the process of correctly performing a subcutaneous injection itself. Particular attention is paid to the features of subcutaneous administration of Tafalgin. An example of a violation of the technique of subcutaneous injection of Tafalgin is given, which can lead to unintentional intramuscular administration of the drug. The authors present the provisions formulated for the optimal method of administering Tafalgin, which allows minimizing technical errors when performing subcutaneous injections in the clinical work of doctors.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>подкожная инъекция</kwd><kwd>техника</kwd><kwd>Тафалгин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>subcutaneous injections</kwd><kwd>technique</kwd><kwd>Tafalgin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Абузарова Г.Р., Сарманаева Р.Р., Алексеева Г.С., Бражникова Ю.В. Клинический случай применения нового селективного µ1-опиоидного анальгетика Тафалгин при лечении хронической боли онкологического генеза. Современная онкология 2022;24(3):314–8. DOI: 10.26442/18151434.2022.3.201913</mixed-citation><mixed-citation xml:lang="en">Abuzarova G.R., Sarmanayeva R.R., Alekseeva G.S., Brazhnicova Y.V. A clinical case of the use of a new selective µ1-opioid analgesic Tafalgin in the treatment of chronic cancer pain. Sovremennaya onkologiya = Journal of Modern Oncology 2022;24(3):313–8. (in Russ.). DOI: 10.26442/18151434.2022.3.201913</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">McKeage J.W., Tan A.Z.H., Taberner A.J. Jet injection through microneedles for large volume subcutaneous delivery. Int J Pharm 2024;667(Pt a):124887. DOI: 10.1016/j.ijpharm.2024.124887</mixed-citation><mixed-citation xml:lang="en">McKeage J.W., Tan A.Z.H., Taberner A.J. Jet injection through microneedles for large volume subcutaneous delivery. Int J Pharm 2024;667(Pt a):124887. DOI: 10.1016/j.ijpharm.2024.124887</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Annersten M., Willman A. Performing subcutaneous injections: a literature review. Worldviews Evid Based Nurs 2005;2(3):122–30. DOI: 10.1111/j.1741-6787.2005.00030.x</mixed-citation><mixed-citation xml:lang="en">Annersten M., Willman A. Performing subcutaneous injections: a literature review. Worldviews Evid Based Nurs 2005;2(3):122–30. DOI: 10.1111/j.1741-6787.2005.00030.x</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Техника инъекций и инфузии при лечении сахарного диабета. национальные рекомендации. Российская ассоциация эндокринологов. Доступно по: https://www.endocrincentr.ru/sites/default/files/all/recomendation/национальные%20рекомендации.%20Техника%20инъекций_РАЭ_2017.pdf (дата доступа: 02.09.2025).</mixed-citation><mixed-citation xml:lang="en">Injection and infusion techniques in the treatment of diabetes mellitus. national guidelines. Russian association of endocrinologists. Available at: https://www.endocrincentr.ru/sites/default/files/all/recomendation/национальные%20рекомендации.%20Техника%20инъекций_РАЭ_2017.pdf (date of access: 02.09.2025). (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">ГОСТ Р ИСО 6009–2013. Иглы инъекционные однократного применения. цветовое кодирование. М.: Стандартинформ, 2014.</mixed-citation><mixed-citation xml:lang="en">National standard of Russia ISO 6009–2013. Single-use injection needles. Color coding. Moscow: Standartinform, 2014. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Курмангулов А.А., Решетникова Ю.С., Багиров Р.Н. и др. Возможности визуализации в качестве бережливого метода в управлении медицинскими организациями. Медицинский вестник Юга России 2019;10(1):6–12. DOI: 10.21886/2219-8075-2019-10-1-6-12</mixed-citation><mixed-citation xml:lang="en">Kurmangulov А.А., Reshetnikova Y.S., Bagirov R.N. et al. Possibilities of visualization as a lean method in the management of medical organizations. Meditsinsky vestnik Yuga Rossii = Medical herald of the south of Russia 2019;10(1):6–12. (in Russ.) DOI: 10.21886/2219-8075-2019-10-1-6-12</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">ISO 6009:2016. Hypodermic needles for single use – сolour coding for identification. Available at: https://www.iso.org/ru/standard/63277.html (date of access: 02.09.2025).</mixed-citation><mixed-citation xml:lang="en">ISO 6009:2016. Hypodermic needles for single use – сolour coding for identification. Available at: https://www.iso.org/ru/standard/63277.html (date of access: 02.09.2025).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Колесников Ю.А., Беспалов А.Ю., Драволина О.А., Звартау Э.Э. Фармакология мю-опиоидов: пути развития. СПб.: ПСПбГМУ, 2021. 206 с.</mixed-citation><mixed-citation xml:lang="en">Kolesnikov Yu.A., Bespalov A.Yu., Dravolina O.A., Zvartau E.E. Pharmacology of mu-opioids: ways of development. St. Petersburg: Pavlov First Saint Petersburg State Medical University, 2021. 206 p.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Van den Beuken-van Everdingen M.H., Hochstenbach L.M., Joosten E.A. et al. update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 2016;51(6):1070–90. DOI: 10.1016/j.jpainsymman.2015.12.340</mixed-citation><mixed-citation xml:lang="en">Van den Beuken-van Everdingen M.H., Hochstenbach L.M., Joosten E.A. et al. update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 2016;51(6):1070–90. DOI: 10.1016/j.jpainsymman.2015.12.340</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston M., Yu E., Kim J. Perineural invasion and spread in head and neck cancer. expert rev anticancer Ther 2012;12(3):359–71. DOI: 10.1586/era.12.9</mixed-citation><mixed-citation xml:lang="en">Johnston M., Yu E., Kim J. Perineural invasion and spread in head and neck cancer. expert rev anticancer Ther 2012;12(3):359–71. DOI: 10.1586/era.12.9</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Usach I., Martinez R., Festini T., Peris J.E. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther 2019;36(11):2986–96. DOI: 10.1007/s12325-019-01101-6</mixed-citation><mixed-citation xml:lang="en">Usach I., Martinez R., Festini T., Peris J.E. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther 2019;36(11):2986–96. DOI: 10.1007/s12325-019-01101-6</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Регистрационное удостоверение препарата Тафалгин. государственный реестр лекарственных средств. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingguid=44a02fe4-6c34-4405-a96a-986f4879b61e (дата доступа: 25.08.2025).</mixed-citation><mixed-citation xml:lang="en">Registration certificate for Tafalgin. State register of Medicines. available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingguid=44a02fe4-6c34-4405-a96a-986f4879b61e (date of access: 25.08.2025). (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">National Institutes of Health Clinical Centre. Patient Education. Giving a subcutaneous injection. Available at: https://patientcareinfusion.com/wp-content/uploads/2020/03/subcutaneous-injection-.pdf (date of access: 25.08.2025).</mixed-citation><mixed-citation xml:lang="en">National Institutes of Health Clinical Centre. Patient Education. Giving a subcutaneous injection. Available at: https://patientcareinfusion.com/wp-content/uploads/2020/03/subcutaneous-injection-.pdf (date of access: 25.08.2025).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Uysal N. Improvement of nursing students’ learning outcomes through scenario-based skills training. Rev Lat Am Enfermagem 2016;24:e2790. DOI: 10.1590/1518-8345.1310.2790</mixed-citation><mixed-citation xml:lang="en">Uysal N. Improvement of nursing students’ learning outcomes through scenario-based skills training. Rev Lat Am Enfermagem 2016;24:e2790. DOI: 10.1590/1518-8345.1310.2790</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Connelly S.T., Schmidt B.L. Evaluation of pain in patients with oral squamous cell carcinoma. J Pain 2004;5(9):505–10. DOI: 10.1016/j.jpain.2004.09.002</mixed-citation><mixed-citation xml:lang="en">Connelly S.T., Schmidt B.L. Evaluation of pain in patients with oral squamous cell carcinoma. J Pain 2004;5(9):505–10. DOI: 10.1016/j.jpain.2004.09.002</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Viola M., Sequeira J., Seica R. et al. Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release 2018;286:301–14. DOI: 10.1016/j.jconrel.2018.08.001</mixed-citation><mixed-citation xml:lang="en">Viola M., Sequeira J., Seica R. et al. Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release 2018;286:301–14. DOI: 10.1016/j.jconrel.2018.08.001</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tyrosyl-arginyl-phenylalanyl-glycinamide. compound summary. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/127510#section=DSSTox-substance-ID (date of access: 25.08.2025).</mixed-citation><mixed-citation xml:lang="en">Tyrosyl-arginyl-phenylalanyl-glycinamide. compound summary. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/127510#section=DSSTox-substance-ID (date of access: 25.08.2025).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Koenitz L., Crean A., Vucen S. Pharmacokinetic differences between subcutaneous injection and intradermal microneedle delivery of protein therapeutics. Eur J Pharm Biopharm 2024;204:114517. DOI: 10.1016/j.ejpb.2024.114517</mixed-citation><mixed-citation xml:lang="en">Koenitz L., Crean A., Vucen S. Pharmacokinetic differences between subcutaneous injection and intradermal microneedle delivery of protein therapeutics. Eur J Pharm Biopharm 2024;204:114517. DOI: 10.1016/j.ejpb.2024.114517</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mercadante S. options for treating pain in cancer patients with dysphagia. Drugs 2017;77(6):629–35. DOI: 10.1007/s40265-017-0710-8</mixed-citation><mixed-citation xml:lang="en">Mercadante S. options for treating pain in cancer patients with dysphagia. Drugs 2017;77(6):629–35. DOI: 10.1007/s40265-017-0710-8</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Косоруков В.С., Абузарова Г.Р., Захарочкина Е.Р. и др. Тафалгин – отечественный инновационный тетрапептидный препарат для подкожного введения: обзор результатов клинических исследований I и II фаз. Опухоли головы и шеи 2022;12(2):89–107. DOI: 10.17650/2222-1468-2022-12-2-89-107</mixed-citation><mixed-citation xml:lang="en">Kosorukov V.S., Abuzarova G.R., Zakharochkina E.R. et al. Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials. Opukholy golovy i shei = Head and Neck Tumors (HNT) 2022;12(2):89–107. (in Russ). DOI: 10.17650/2222-1468-2022-12-2-89-107</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Fürst P., Lundström S., Klepstad P., Strang P. Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center. BMC Palliat Care 2020;19(1):172. DOI: 10.1186/s12904-020-00681-3</mixed-citation><mixed-citation xml:lang="en">Fürst P., Lundström S., Klepstad P., Strang P. Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center. BMC Palliat Care 2020;19(1):172. DOI: 10.1186/s12904-020-00681-3</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
